GenAns Biotech raises hundreds of millions of yuan in Series A for gene therapies
What's the deal? GenAns Biotech, a gene therapy company focused on central nervous system (CNS) and ophthalmic diseases, has closed a Series A round worth hundreds of millions of yuan. Taiping Healthcare FundDealroom has a profile for this one. Try Dealroom → led the round, with returning shareholder Huatai Zijin's fund following on.
Who else joined? Gaorong CapitalDealroom has a profile for this one. Try Dealroom → and several other new and existing shareholders also participated in the round, which was announced in July 2026.
What's the endgame? The company develops gene-based treatments for CNS disorders and eye diseases, areas where conventional drugs often struggle to reach or address the underlying cause.
The signal: The backing from a healthcare-focused fund alongside repeat investors points to continued investor appetite for gene therapy platforms targeting hard-to-treat conditions.
Read more: IT桔子
Image credit: National Institutes of Health (NIH)
